

Antimicrobial Stewardship Matters

Antimicrobial Stewardship | November 2024

Antimicrobial resistance is invisible – patient harm is not

The Facts

Antimicrobial misuse and overuse accelerate antibiotic resistance, which has now been declared a global health threat. An estimated one out of 16 hospitalized patients acquire a multi-drug resistant (MDR) infection in Canada every year¹. MDR infections are associated with higher patient morbidity, mortality and health care costs^{2,3}.

The death toll from antimicrobial resistance is increasing:

Year	Annual global patient deaths ⁴	
	Directly attributable to resistance	Associated with resistance
2021	1.14 million	4.71 million
Projected for 2050	1.91 million	8.22 million

What Alberta Health Services is doing

On May 1, 2024, AHS announced the launch of a newly integrated provincial Antimicrobial Stewardship Program (ASP), under the Quality and Healthcare Improvement (QHI) portfolio. The ASP will be implemented in a phased approach across all AHS acute care sites. You can find more information about the ASP on [Insite](#).

Do your part

Before prescribing antibiotics, ask yourself three questions:

1. Does my patient need antibiotics?

Yes	No
<ul style="list-style-type: none">Confirmed bacterial infectionFever in a critically ill/septic patient	<ul style="list-style-type: none">Infection commonly caused by virusesBacterial colonization (eg. asymptomatic bacteriuria)Fever in a stable patient with no clear infectious source

2. What is the harm of prescribing antibiotics?

- Increased patient and population level antibiotic resistance
- C. difficile* infection (CDI) – Antibiotics are the single greatest risk factor for CDI with 96 per cent of CDI patients prescribed an antibiotic in the preceding 14 days⁵
- Antibiotic adverse effects and toxicities – one in five inpatients who receive an antibiotic will experience an adverse effect⁶

3. How do I minimize antibiotic-related harm?

- Choose the narrowest spectrum agent that will cover the responsible pathogen(s)
- Prescribe the shortest course of therapy that is still effective
 - Short course therapy is non-inferior to longer durations for many infections and has the added benefits of limiting antibiotic exposure and minimizing antibiotic resistance
- Reassess patient at 48 to 72 hours for de-escalation based on culture & susceptibility results and for IV to PO switch as appropriate.

References are available upon request



Missed an issue?

Explore our full newsletter collection online:
[Antimicrobial Stewardship Matters](#)